Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin

Xenobiotica

Volumn 42, Issue 5, 2012, Pages 496-501

  Choi, Chang Ik ^a   Lee, Yun Jeong ^a   Lee, Hye In ^a   Kim, Bo Hye ^a   Kim, Mi Jeong ^a   Jang, Choon Gon ^a   Bae, Jung Woo ^b   Lee, Seok Yong ^a  

^a Sungkyunkwan University   (South Korea)

^b Keimyung University   (South Korea)

Author keywords

genetic polymorphism; pharmacokinetics; Pitavastatin; SLCO1B1

Indexed keywords

DRUG METABOLITE; ORGANIC ANION TRANSPORTER 2; PITAVASTATIN; PITAVASTATIN LACTONE; UNCLASSIFIED DRUG; ORGANIC ANION TRANSPORTER; QUINOLINE DERIVATIVE; SLCO1B1 PROTEIN, HUMAN;

ALLELE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; GENETICS; ORAL DRUG ADMINISTRATION; TIME;

ADMINISTRATION, ORAL; ALLELES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ORGANIC ANION TRANSPORTERS; QUINOLINES; TIME FACTORS;

EID: 84859341661     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.632030     Document Type: Article

References (32)

1. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, Matsuno S, Yawo H. (1999). Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 274:17159-17163.
2. Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, Wada Y, Yokoo N, Sato F, Kimata H, Kitahara M, Toyoda K, Sakashita M, Saito Y. (1997). Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3- methylglutaryl-coenzyme A reductase. Arzneimittelforschung 47:904-909. (Pubitemid 27357013)
3. Choi JH, Lee MG, Cho JY, Lee JE, Kim KH, Park K. (2008). Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin Pharmacol Ther 83:251-257. (Pubitemid 351147710)
4. Choi MK, Shin HJ, Choi YL, Deng JW, Shin JG, Song IS. (2011). Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica 41:24-34.
5. Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG, Jang IJ. (2005). Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 78:342-350.
6. Cui Y, König J, Leier I, Buchholz U, Keppler D. (2001). Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626-9630.
7. Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH, Shin JG. (2008). The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: The contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics 18:424-433. (Pubitemid 351535943)
8. Fujino H, Yamada I, Shimada S, Nagao T, Yoneda M. (2002). Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans. Arzneimittelforschung 52:745-753.
9. Fujino H, Yamada I, Shimada S, Yoneda M, Kojima J. (2003). Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: Human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 33:27-41. (Pubitemid 36071761)
10. Hirano M, Maeda K, Shitara Y, Sugiyama Y. (2004). Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139-146. (Pubitemid 39287793)
11. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG. (1999). A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161-37168.
12. Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y. (2007). SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 82:541-547. (Pubitemid 47622520)
13. Kajinami K, Mabuchi H, Saito Y. (2000). NK-104: A novel synthetic HMG-CoA reductase inhibitor. Expert Opin Investig Drugs 9:2653-2661.
14. Kalliokoski A, Niemi M. (2009). Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693-705.
15. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. (2005). Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15:513-522. (Pubitemid 41017600)
16. Kimata H, Fujino H, Koide T. (1998). Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats. Xenobio Metab Dispos 13:484-98.
17. Kojima J, Fujino H, Abe H, Yosimura M, Kanda H, Kimata H. (1999). Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Biol Pharm Bull 22:142-150. (Pubitemid 29114030)
18. König J, Cui Y, Nies AT, Keppler D. (2000). A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 278:G156-G164. (Pubitemid 30108080)
19. Michalski C, Cui Y, Nies AT, Nuessler AK, Neuhaus P, Zanger UM, Klein K, Eichelbaum M, Keppler D, Konig J. (2002). A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 277:43058-43063. (Pubitemid 35285687)
20. Mukhtar RY, Reid J, Reckless JP. (2005). Pitavastatin. Int J Clin Pract 59:239-252. (Pubitemid 40331227)
21. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivistö KT. (2004). High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:429-440. (Pubitemid 38971233)
22. Niemi M. (2007). Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8:787-802.
23. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y. (2003). Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554-565. (Pubitemid 37249126)
24. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T. (2002). Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302:804-813. (Pubitemid 34787251)
25. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. (2005). Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: In vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33:434-439. (Pubitemid 40279945)
26. Pasanen MK, Neuvonen PJ, Niemi M. (2008). Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 9:19-33. (Pubitemid 351560529)
27. Shimada S, Fujino H, Morikawa T, Moriyasu M, Kojima J. (2003). Uptake mechanism of pitavastatin, a new inhibitor of HMG-CoA reductase, in rat hepatocytes. Drug Metab Pharmacokinet 18:245-251.
28. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A. (2000). Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273:251-260. (Pubitemid 30426895)
29. Tirona RG, Leake BF, Merino G, Kim RB. (2001). Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276:35669-35675.
30. Tirona RG, Leake BF, Wolkoff AW, Kim RB. (2003). Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223-228. (Pubitemid 36008932)
31. Tirona RG. (2005). Ethnic differences in statin disposition. Clin Pharmacol Ther 78:311-316.
32. Yang GP, Yuan H, Tang B, Zhang W, Wang LS, Huang ZJ, Ou-Yang DS, Zhang GX, Zhou HH. (2010). Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients. Acta Pharmacol Sin 31:382-386.